Conmed’s recurring consumables franchise and niche leadership create substantial recovery upside, but floating-rate debt and orthopedic execution determine whether CNMD remains discounted or rerates.
Overview
Conmed Corporation (CNMD) is a focused medical-technology company serving General Surgery and Orthopedic Surgery, which represented 58% and 42% of FY2025 sales, respectively. Its model is unusually recurring for a device manufacturer: approximately 85% of sales come from high-margin single-use consumables, while capital equipment represents roughly 15%. AirSeal, Buffalo Filter, and BioBrace provide the principal growth platforms, supported by clinical switching costs, more than 1,000 patents, and regulatory tailwinds for surgical smoke evacuation. Q1 FY2026 sales declined 1.3% reported to $317.0 million, but excluding the $15.5 million GI-exit headwind, organic constant-currency growth was 2.1%; adjusted EPS of $0.89 exceeded consensus of $0.82–$0.84. Management raised the lower end of 2026 revenue guidance to $1.350–$1.375 billion, lifted organic constant-currency growth guidance to 5.0%–6.5%, and reaffirmed adjusted EPS guidance of $4.30–$4.45. **The principal issue is balance-sheet pressure:** refinancing replaced low-cost convertibles with floating-rate debt. At $37.48, CNMD trades at approximately 8.6x FY2026 midpoint EPS versus a 32.7x peer average. **Successful deleveraging and orthopedic recovery are the key catalysts** for substantial multiple normalization.